文献速递白血病淋巴瘤

国际协作研究确定儿童模糊谱系白血病的治疗策略

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
PubMed 文献 · Blood · 2018-05-02

这项回顾性多国研究纳入233例儿童模糊谱系白血病(ALAL)患者,比较不同治疗类型的预后。以急性淋巴细胞白血病(ALL)方案为主治疗者的5年无事件生存(EFS)优于AML型或联合型治疗;推荐多数儿童ALAL采用ALL型方案,包括CD19+病例。

要点

  • ALL型为主治疗的5年EFS为80%±4%,优于AML型36%±7.2%和联合型50%±12%。
  • 排除ALL或AML特异性基因融合后,CD19+白血病ALL型治疗5年EFS为83%±5.3%,AML型0%±0%和联合型28%±14%。
  • 推荐多数儿童ALAL采用ALL型方案;CD19-且无其他淋系特征的少数病例首选AML型治疗。

核心结论

  • 推荐多数儿童ALAL患者采用ALL型方案治疗,包括CD19+ ALAL病例;CD19-且无其他淋系特征的少数ALAL病例首选AML型治疗。
  • 未证实移植的总体获益,可对治疗反应差的某些患者引入移植;因未找到改变治疗类型的明确指标,仅在缓解诱导后原始细胞≥5%的病例考虑更改治疗类型。
  • 研究结果为开展前瞻性试验提供了基础。

研究设计与样本

  • 国际柏林-法兰克福-明斯特模糊谱系白血病研究(iBFM-AMBI2012)的回顾性多国研究,纳入233例儿童ALAL患者。
  • 采用生存统计比较不同亚组和治疗类型的预后。

主要发现

  • ALL型为主治疗患者的5年EFS为80%±4%,优于接受AML型或联合型治疗者(分别为36%±7.2%和50%±12%)。
  • 排除ALL或AML特异性基因融合后,CD19+白血病ALL型为主治疗的5年EFS为83%±5.3%,AML型为0%±0%,联合型为28%±14%。
  • ALL型治疗的优势在单群体混合表型ALAL(采用世界卫生组织(WHO)和/或欧洲白血病免疫分型组(EGIL)定义)及双系ALAL中均有记录。

关键数值与推荐

  • 推荐多数儿童ALAL患者采用ALL型方案治疗,包括CD19+ ALAL病例。
  • CD19-且无其他淋系特征的少数ALAL病例首选AML型治疗。
  • 未证实移植的总体获益,可对治疗反应差的某些患者引入移植。
  • 仅在缓解诱导后原始细胞≥5%的病例考虑更改治疗类型。

临床怎么用

  • 儿童ALAL多数可采用ALL型方案治疗,包括CD19+病例;CD19-且无其他淋系特征者首选AML型治疗。
  • 移植无总体获益,可考虑用于治疗反应差的某些患者。
  • 缓解诱导后原始细胞≥5%时可考虑更改治疗类型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2% and 50% ± 12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5-year EFS of CD19+ leukemia was 83% ± 5.3% on ALL-type primary treatment compared with 0% ± 0% and 28% ± 14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using World Health Organization and/or European Group for Immunophenotyping of Leukemia definitions) and bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19+ ALAL. AML-type treatment is preferred in a minority of ALAL cases with CD19- and no other lymphoid features. No overall benefit of transplantation was documented, and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change in treatment type, this is to be considered only in cases with ≥5% blasts after remission induction. The results provide a basis for a prospective trial.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hrusak O, de Haas V, Stancikova J, et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018. PMID: 29720486. doi:10.1182/blood-2017-12-821363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。